secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001193125-23-145622
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio receives FDA clearance for second CABA-201 IND, Phase 1/2 trial in myositis
--------------------------------------------------------------------------------

- FDA cleared IND for CABA-201 in active idiopathic inflammatory myopathy (myositis); second IND clearance within two months.
- Phase 1/2 trial to enroll 18 patients across three subtypes: dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy.
- Initial dose 1 x 10^6 cells/kg, informed by preclinical data and Lancet Rheumatology publication.
- Myositis subtypes impact ~66,000 patients in US; current treatments often inadequate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523145622/0001193125-23-145622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523145622/d505525d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-145622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer